- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Chirocaine
(United States) [Available]Synonyms :
levobupivacaine
Class :
Local injectable anesthetics
Dosage forms and strengths
Infusion solution/injection-7.5 mg/mL, 5 mg/mL, 2.5 mg/mL (10 ml)
Premix solution for infusion- 1.25 mg/mL, 0.625 mg/mL
(200 ml,100 ml)
Indicated for surgical anesthesia
Intrathecal- Administer 3 mL of solution containing 0.5% concentration
Epidural-Cesarean: Administer 0.5% solution within the range of 15-30 mL, with a maximum solitary dose of 150 mg
Surgery (not cesarean): Administer 10-20 mL of a solution containing 0.5%- 0.75% , with a maximum solitary dose of 150 mg
Extended surgical procedures could necessitate a maximum total dosage of 400 mg within a 24-hours
Dental- Administer 5 to 10 mL of a solution with a concentration between 0.5% -0.75%
Local infiltration-Administer 1-60 mL of a solution with 0.25 % concentration, with a maximum dosage not exceeding 150 mg (peribulbar block)
Ophthalmic- Administer 5-15 ml of a solution with 0.75 % concentration
Peripheral nerve-Administer 1-40 ml of a solution with 0.25% concentration or 1-30 ml of a solution with a 0.5% concentration with a maximum dosage not exceeding 150 mg
Indicated for pain management
Peri & postoperative pain (epidural infusion)- Administering a solution of 0.0625% at a rate of 10 -15 mL every hour, alternatively, infusing a 0.125% solution at the same rate of 10-15 mL every hour, or utilizing a 0.25% solution at 5-7.5 mL every hour
Administer at a maximum rate of 18.75 mg every hour
Maintain maximum cumulative dose at 400 mg each day Nevertheless, patients have shown good tolerance to postoperative dosages as high as 570 mg/24 hours (epidural bolus) in labor pain
: Administer 6-20 ml of solution with 0.25 % concentration
(epidural infusion) in Labor pain-Administer a solution containing 0.0625% concentration at a rate of 10-15 mL every hour
alternatively, administer a solution with 0.125% concentration at a rate of 4-10 mL every hour
Administer at a maximum rate of 12.5 mg every hour Maintain maximum cumulative dose at 400 mg each day
Dosage forms and strengths
Infusion solution/injection-7.5 mg/mL, 5 mg/mL, 2.5 mg/mL (10 ml)
Premix solution for infusion- 1.25 mg/mL, 0.625 mg/mL
(200 ml,100 ml)
Indicated for surgical anesthesia
Local infiltration (iliohypogastric block/ Ilioinguinal) For children age greater than 6 months- less than 12 years
Administer 0.5 mL/kg/side solution with a concentration of 0.25%
The maximum dosage not to exceed 1.25 mg/kg/side
Administer 0.25 mL/kg/side solution with a concentration of 0.5%
The maximum dosage not to exceed 1.25 mg/kg/side
Refer adult dosing
may increase the risk or severity of methemoglobinemia when miltefosine is combined
may increase the QTc prolonging effect of QT-prolonging agents
may increase the toxic effect of Methemoglobinemia Associated Agents
may have an increasingly adverse effect when combined with bupivacaine
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
The potential for increased CNS depression risk or seriousness occurs when levobupivacaine is used together with pinazepam
The potential for increased CNS depression risk or seriousness occurs when levobupivacaine is used together with pipecuronium
The potential for CNS depression may enhanced when levobupivacaine is used together with fencamfamin
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
may increase the toxic effect
may increase the arrhythmogenic effect of inhalational anesthetics
may increase the toxic effect of methemoglobinemia associated agents
may have an increasingly adverse effect when combined with local anesthetics
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the toxic effect of Methemoglobinemia Associated Agents
may increase the hypotensive effect of QT-Prolonging Inhalational Anesthetics
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the toxic effect of Methemoglobinemia Associated Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
acetaminophen/doxylamine/dextromethorphan
may enhance the toxic effect of Methemoglobinemia Associated Agents
may decrease the therapeutic effect of anesthetics
When levobupivacaine and abaloparatide are combined, the risk or seriousness of adverse events will rise
When levobupivacaine and acebutolol are combined, the risk or seriousness of adverse events will rise
When levobupivacaine and aliskiren are combined, the risk or seriousness of adverse events will rise
When levobupivacaine and amifostine are combined, the risk or seriousness of adverse events will rise
When levobupivacaine and amlodipine are combined, the risk or seriousness of adverse events will rise
levobupivacaine and acetophenazine together have the potential to increase risk or seriousness of CNS depression
levobupivacaine's rate of excretion may be reduced by acetylsalicylic acid, which might raise the serum level
levobupivacaine has the potential to lower the rate of excretion of aclidinium, leading to a possible elevation in serum levels
levobupivacaine has the potential to lower the rate of excretion of acrivastine, leading to a possible elevation in serum levels
When used with acyclovir, levobupivacaine's metabolism may be reduced
When adagrasib and levobupivacaine are combined, the risk or seriousness of methemoglobinemia could rise
When combined with adalimumab, levobupivacaine's metabolism can be enhanced
levobupivacaine's rate of excretion may be reduced by defovir dipivoxil, which might raise the serum level
Combining afatinib with levobupivacaine may enhance the risk or seriousness of methemoglobinemia
levobupivacaine has the potential to lower the rate of excretion of ancestim, potentially leading to elevated levels of serum
The combination of levobupivacaine can lead to a reduction in the metabolism of antipyrine
antrafenine has the potential to reduce the rate of excretion of levobupivacaine, potentially leading to elevated levels of serum
When apalutamide is combined with levobupivacaine, there is a potential for a reduction in the concentration serum of levobupivacaine
Actions and Spectrum:
Action:
like other local anesthetics, levobupivacaine works by blocking the generation and conduction of nerve impulses. It does this by inhibiting sodium ion influx through the voltage-gated sodium channels in nerve cell membranes. Sodium channels are crucial in transmitting nerve signals, including pain signals, to the brain. Through inhibiting these pathways, levobupivacaine hinders the conveyance of pain impulses from the nerves to the brain. This leads to a transient numbing effect and alleviation of pain in the specific region of its application.
Spectrum:
Local Anesthesia: levobupivacaine is primarily used as a local anesthetic. It hinders nerve signal transmission by preventing the entry of sodium ions through sodium channels present in the membranes of nerve cells. This prevents the generation and propagation of nerve impulses, leading to temporary loss of sensation in the targeted area.
Frequency not defined
Blurred vision
Paraplegia
Paraesthesia
Syncope
Somnolence
Unconsciousness
Convulsions
Hypersensitivity reactions
Anaphylaxis
Allergic reaction
Back pain
Pyrexia
Headache
Dizziness
Vomiting
Anaemia
Nausea
Hypotension
Black Box Warning:
